Sie befinden sich hier
Inhalt
19th May 2023
Two Collaborative Research Centers “Understanding and targeting resistance in glioblastoma” (CRC 1389), and “From nociception to chronic pain: structure-function properties of neural pathways and their reorganization” (CRC 1158) and the CRC/Transregio “Losing and Regaining Control over Drug Intake – From Trajectories to Mechanisms to Interventions” (CRC/TRR 265) receive funding from the German Research foundation for four more years.
It is the second funding phase for the Collaborative Research Centre “Understanding and targeting resistance in glioblastoma” (CRC 1389), with its studies aiming at combating resistance to the treatment of these malignant brain tumours. As in the first funding period spokesperson for the CRC 1389 is Prof. Dr. Wolfgang Wick, executive director of the Neurology Clinic at Heidelberg University Hospital and Head of the Clinical Cooperation Unit Neurooncology at the German Cancer Research Center. The deputy spokesperson of the CRC 1389 continues to be Prof. Dr. Michael Platten, medical director of the Department of Neurology at the Medical Faculty Mannheim, Heidelberg University and Head of the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center.
It is the third funding phase for the Collaborative Research Centre “From nociception to chronic pain: structure-function properties of neural pathways and their reorganization” (CRC 1158). The scientists involved examine how acute pain turns into chronic pain. They focus on changes in nerve cells and nerve pathways. As before, the spokesperson of the Collaborative Research Center is Prof. Dr. Rohini Kuner, Managing Director of the Institute of Pharmacology at the Heidelberg Medical Faculty. The deputy spokesperson of the SFB 1158 continues to be Prof. Dr. Dr. Dr. Herta Flor, Scientific Director of the Institute of Neuropsychology and Clinical Psychology at the Central Institute of Mental Health.
It is the second funding phase for the CRC/Transregio “Losing and Regaining Control over Drug Intake – From Trajectories to Mechanisms to Interventions”. The research studies in the CRC/TRR 265 aim for a better understanding of the mechanisms responsible for people losing control over their drug consumption. The researchers work at the behavioural, cognitive and neuroscientific level to identify the triggers and influencing factors for such loss of control. The new spokesperson is Prof. Dr. Rainer Spanagel, Scientific Director of the Institute for Psychopharmacology at the Central Institute of Mental Health and holder of a professorship at the Mannheim Medical Faculty of the University of Heidelberg
Press release at Heidelberg University:
19.05.2023 DFG funding: two Collaborative Research Centers and two CRC/Transregio successful
News release at the Central Institute of Mental Health:
19.05.23 Collaborative Research Centers on Addiction and Pain extended